Skip to content

Efficacy Testing of Collagen and Zhuyin Drinks

Efficacy Testing of Collagen and Zhuyin Drinks

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04266405
Enrollment
50
Registered
2020-02-12
Start date
2020-03-09
Completion date
2020-12-01
Last updated
2020-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Condition

Brief summary

To assess collagen and zhuyin drink on skin & body condition improvement

Interventions

DIETARY_SUPPLEMENTPlacebo drink

consume 1 bottle (50 mL) per day for 28 days

DIETARY_SUPPLEMENTCollagen Cubilose Drink

consume 1 bottle (50 mL) per day for 28 days

Sponsors

TCI Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

Single

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy adults aged above 20 years old

Exclusion criteria

* Subject who is not willing to participate in this study. * Patients with diseases of the skin, heart, liver, kidney, endocrine and other organs and patients with mental illness (according to medical history). * Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder. * Female who is pregnant or nursing or planning to become pregnant during the course of the study. * Received facial laser therapy, chemical peeling or UV overexposure in the past 4 weeks. * Vegetarian * Subjects who have large spots (area \>3 square centimeter) or abnormal acne.

Design outcomes

Primary

MeasureTime frameDescription
The change of metallopeptidase inhibitor 1Change from Baseline skin brightness at 4 weeksVenous blood was sampled to measure concentrations of metallopeptidase inhibitor 1.
The change of interleukin-6Change from Baseline skin brightness at 4 weeksVenous blood was sampled to measure concentrations of interleukin-6.
The change of interleukin-8Change from Baseline skin brightness at 4 weeksVenous blood was sampled to measure concentrations of interleukin-8.
The change of Tumor necrosis factorChange from Baseline skin brightness at 4 weeksVenous blood was sampled to measure concentrations of Tumor necrosis factor.
The change of Matrix metalloproteinase-1Change from Baseline skin brightness at 4 weeksVenous blood was sampled to measure concentrations of Matrix metalloproteinase-1 .
The change of skin moistureChange from Baseline skin moisture at 4 weeksCorneometer® CM825 was utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120
The change of skin wrinklesChange from Baseline skin wrinkles at 4 weeksVISIA Complexion Analysis System was utilized to measure wrinkles. Units: arbitrary units
The change of skin collagen densityChange from Baseline skin collagen density at 4 weeksDermaLab® USB - 20 MHz High Freq. Ultrasound probe was utilized to scan and analyze skin collagen density. Units:Intensity score
The change of TEWLChange from Baseline TEWL at 4 weeksTewameter® TM 300 was utilized to measure TEWL. Units: g/h/m2
The change of skin brightnessChange from Baseline skin brightness at 4 weeksGlossymeter GL 200 was utilized to measure skin brightness. Units: arbitrary units

Secondary

MeasureTime frameDescription
The change of skin poresChange from Baseline skin pores at 4 weeksVISIA Complexion Analysis System was utilized to measure skin pores. Units: arbitrary units
The change of skin spotsChange from Baseline skin spots at 4 weeksVISIA Complexion Analysis System was utilized to measure skin spots. Units: arbitrary units
The change of red areasChange from Baseline red areas at 4 weeksVISIA Complexion Analysis System was utilized to measure red areas. Units: arbitrary units
The change of skin textureChange from Baseline skin texture at 4 weeksVISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026